Physician profile
Anna Nikachina
NPI 1811284102
$6,238.44
in general payments reported to CMS, 2019-2025
11 companies · $611 in 2025
The $611 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2021: $15.59 · 2022: $2,357 · 2023: $17.95 · 2024: $3,007 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,820 · Food and Beverage: $1,801 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,819.99 |
| Food and Beverage | $1,801.22 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,683.27 | 2021-2025 | Wavewriter Alpha Prime 16, General - Therapies, Intracept |
| Curonix LLC | $1,505.26 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $491.34 | 2024-2025 | Sprint Pns System |
| Nevro Corp. | $195.75 | 2019 | |
| Abbvie INC. | $110.34 | 2024-2025 | |
| Painteq LLC | $108.23 | 2024 | Painteq |
| Valinor Pharma, LLC | $64.28 | 2024-2025 | Movantik |
| Ziehm-Orthoscan, INC. | $33.48 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.95 | 2023 | Ztlido |
| Fidia Pharma USA INC. | $14.39 | 2024 | Hymovis |
| Collegium Pharmaceutical, INC. | $14.15 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Nikachina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.